Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

ONTX was reduced by Zacks.com  from a “acquire” score to a “hold” score in a research note released to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on discovering and also developing small particle medicine candidates to treat cancer cells. The Firm‘s products under different stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts likewise just recently discussed the company. Noble Financial editioned a “purchase” ranking and also issued a $11.00 rate goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “acquire” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving average rate of $2.90 and a two-hundred day relocating average cost of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) profits per share for the quarter, covering experts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and an adverse web margin of 8,294.27%. The firm had profits of $0.06 million during the quarter, contrasted to the agreement estimate of $0.06 million. During the exact same quarter in the previous year, the company published ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A number of hedge funds have actually recently dealt shares of ONTX. GSA Resources Allies LLP bought a new placement in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Management LP purchased a new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC acquired a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a new setting in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional capitalists have 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition as well as growth of oncology therapeutics. It focuses on finding and also creating tiny molecule drug candidates to deal with cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For additional information regarding research offerings from Zacks Investment Research, visit Zacks.com.

This instant news alert was generated by narrative science modern technology and also economic data from Market in order to give viewers with the fastest and most exact coverage. This story was examined by Market’s content group prior to magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Before you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s premier as well as best executing research analysts as well as the stocks they suggest to their customers every day. Market has identified the five stocks that top experts are silently murmuring to their clients to acquire currently prior to the more comprehensive market catches on … as well as Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics presently has a “Buy” score among experts, premier analysts believe these five stocks are better buys.